Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06675136
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Target Recruit Count
- 152
- Registration Number
- NCT06656598
- Locations
- 🇫🇷
Caen - CHU, Caen, France
🇫🇷Caen - CRLCC, Caen, France
🇫🇷Créteil - CHI, Créteil, France
A Study of Ifinatamab Deruxtecan in Subjects With Advanced or Metastatic ESCC (IDeate-Esophageal01)
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 510
- Registration Number
- NCT06644781
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-11
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Rima Patel
- Target Recruit Count
- 15
- Registration Number
- NCT06637306
- Locations
- 🇺🇸
Mount Sinai Health System, New York, New York, United States
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06632951
- Locations
- 🇺🇸
Highlands Oncology Group - Springdale /ID# 270290, Springdale, Arkansas, United States
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
- Conditions
- Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Prostate CarcinomaAdvanced SarcomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8
- Interventions
- Drug: AbemaciclibProcedure: BiopsyProcedure: Biospecimen CollectionDrug: FulvestrantProcedure: Bone ScanDrug: CarboplatinDrug: OlaparibProcedure: EchocardiographyDrug: GemcitabineDrug: PemetrexedDrug: ExemestaneDrug: LetrozoleDrug: GefitinibProcedure: Multigated Acquisition ScanOther: Survey AdministrationDrug: TamoxifenDrug: TemozolomideDrug: PaclitaxelDrug: OsimertinibDrug: Pegylated Liposomal Doxorubicin Hydrochloride
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06630325
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 680
- Registration Number
- NCT06623422
- Locations
- 🇺🇸
Beacon Cancer Care ( Site 0127), Post Falls, Idaho, United States
🇺🇸Thompson Cancer Survival Center ( Site 0168), Knoxville, Tennessee, United States
🇦🇺Tasman Oncology Research ( Site 2104), Southport, Queensland, Australia
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Genmab
- Target Recruit Count
- 530
- Registration Number
- NCT06619236
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 404
- Registration Number
- NCT06616532
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, China
🇨🇳Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
🇨🇳The First Affiliated Hospital Of Ningbo University, Ningbo, Zhejiang, China
Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 30
- Registration Number
- NCT06604858
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.